Evidence and Values: Requirements for Public Reimbursement of Drugs for Rare Diseases- A Case Study in Oncology- Reply

Main Article Content

Andreas Laupacis

Keywords

.

Abstract

.

Abstract 114 | PDF Downloads 46

References

1. Drummond M, Evans B, LeLorier J, Karakiewicz P, Martin D, Tugwell P, MacLeod S. Evidence and values: Requirements for public reimbursement of drugs for rare diseases – A case study in oncology. Can J Clin Pharmacol Vol 16(2) Summer 2009; May 13, 2009:e273-81.
2. http://www.nice.org.uk/getinvolved/patientandp ublicinvolvement/opportunitiestogetinvolved/citi zenscouncil/citizens_council.jsp (Accessed on: March 14, 2009).
3. http://www.tlv.se/in-english/ (Accessed on: March 14, 2009).
4. Elston J, Taylor RS. Use of surrogate markers in cost-effectiveness models: A review of United Kingdom health technology assessment reports. International Journal of Technology Assessment in Health Care 2009;25:6-13.
5. http://clinicaltrials.gov/ct2/show/NCT00455104 (Accessed on : March 14, 2009).
6. Stolk EA, Brouwer WB, Busschbach JJ. Rationalizing rationing: economic and other considerations in the debate about funding of Viagra. Health Policy 2002;59:53-63.
7. http://www.cadth.ca/media/cdr/complete/cdr_co mplete_Tarceva_Dec605.pdf (Accessed on: March 14, 2009).
8. Henry DA, Hill SR, Harris A. Drug prices and value for money: The Australian Pharmaceutical Benefits Scheme. JAMA 2005;294:2630-2632.
9. Devlin N, Parkin D. Does NICE have a costeffectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics 2004; 13:437-452.